Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 01, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will present a corporate overview and host investor meetings during the Jefferies Healthcare Conference, held in New York City, from June 6 - 9, 2017.
Matt Kapusta, chief executive officer, will present on Friday, June 9, 2017 at 8:00 am EDT. The live webcast of the presentation can be accessed through the link displayed in the Investor Section of uniQure website at http://uniqure.com/investors-newsroom/events-presentations.php. A replay of the webcast will be available within 24 hours following the event, and will remain available for at least two weeks.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
